Loading
NASDAQHealthcareBiotechnology
Latest quote
$148.18
+$3.02 · +2.08%
Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders. The company's pipeline features rusfertide (PTG-300), an injectable hepcidin mimetic currently undergoing Phase II clinical trials for the management of polycythemia vera, hereditary hemochromatosis, and other blood-related ailments. Also in Phase II development is PN-943, an oral peptide engineered as a specific antagonist of alpha-4-beta-7 integrin, intended for addressing inflammatory bowel disease (IBD). Furthermore, they are progressing PN-235, an orally administered antagonist specifically targeting the interleukin-23 receptor, designed for both IBD and various non-IBD therapeutic applications. Protagonist Therapeutics maintains a licensing and collaborative agreement with Janssen Biotech, Inc. Founded in 2006, the company's headquarters are located in Newark, California.
Previous close
$148.18
+$3.02 · +2.08%
Regular session · ET · Market data may be delayed.
Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders. The company's pipeline features rusfertide (PTG-300), an injectable hepcidin mimetic currently undergoing Phase II clinical trials for the management of polycythemia vera, hereditary hemochromatosis, and other blood-related ailments. Also in Phase II development is PN-943, an oral peptide engineered as a specific antagonist of alpha-4-beta-7 integrin, intended for addressing inflammatory bowel disease (IBD). Furthermore, they are progressing PN-235, an orally administered antagonist specifically targeting the interleukin-23 receptor, designed for both IBD and various non-IBD therapeutic applications. Protagonist Therapeutics maintains a licensing and collaborative agreement with Janssen Biotech, Inc. Founded in 2006, the company's headquarters are located in Newark, California.
Day range
Current $148.18
52-week range
Current $148.18
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
2
Overpriced
Sentiment
59
Mixed
Risk
46
Elevated Risk
Momentum
80
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders. The company's pipeline features rusfertide (PTG-300), an injectable hepcidin mimetic currently undergoing Phase II clinical trials for the management of polycythemia vera, hereditary hemochromatosis, and other blood-related ailments. Also in Phase II development is PN-943, an oral peptide engineered as a specific antagonist of alpha-4-beta-7 integrin, intended for addressing inflammatory bowel disease (IBD). Furthermore, they are progressing PN-235, an orally administered antagonist specifically targeting the interleukin-23 receptor, designed for both IBD and various non-IBD therapeutic applications. Protagonist Therapeutics maintains a licensing and collaborative agreement with Janssen Biotech, Inc. Founded in 2006, the company's headquarters are located in Newark, California.
Day range
Current $148.18
52-week range
Current $148.18
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 46.02M USD | 434.43M USD | 60M USD | 26.58M USD | 27.36M USD |
| Cost of goods sold | 1.23M USD | — | — | — | — |
| Gross profit | 44.79M USD | 434.43M USD | 60M USD | 26.58M USD | 27.36M USD |
| Research and development | 159.29M USD | 138.13M USD | 120.16M USD | 126.22M USD | 126.01M USD |
| Selling, general, and administrative | 44.85M USD | 43.46M USD | 33.49M USD | 31.74M USD | 27.2M USD |
| Operating expenses | 202.92M USD | 181.59M USD | 153.65M USD | 157.95M USD | 153.2M USD |
| Interest income | 28.79M USD | 26.32M USD | 14.9M USD | 4.06M USD | 443K USD |
| Depreciation and amortization | 1.23M USD | 826K USD | 3.31M USD | 3.37M USD | 2.78M USD |
| Operating income | −158.13M USD | 252.84M USD | −93.65M USD | −131.37M USD | −125.85M USD |
| Net income | −130.15M USD | 275.19M USD | −78.96M USD | −127.39M USD | −125.55M USD |
Company facts updated Sep 12, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Funds reporting this stock among their holdings, ordered by reported position size.
iShares Core S&P Small-Cap ETFIJR583.68M0.52%107.03B USD0.06%$142.19+0.53%
Vanguard Morningstar Total Stock Market ETFVTI280.41M0.01%2.3T USD0.03%$376.31+0.82%
iShares Russell 2000 ETFIWM226.8M0.29%77.55B USD0.19%$288.89+0.41%
Vanguard Morningstar Small-Cap ETFVB202.07M0.11%183.4B USD0.03%$293.45+0.78%
State Street SPDR S&P Biotech ETFXBI140.18M1.33%10.57B USD0.35%$156.2-0.40%
Vanguard Morningstar Small-Cap Growth ETFVBK116.95M0.26%43.8B USD0.05%$340.69+0.80%
Vanguard Extended Market ETFVXF95.1M0.10%93.7B USD0.05%$237.76+0.68%
iShares S&P Small-Cap 600 Growth ETFIJT88.74M1.05%8.02B USD0.18%$166.46+0.48%iShares Core S&P Small-Cap ETFIJRVanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Morningstar Small-Cap ETFVBState Street SPDR S&P Biotech ETFXBIVanguard Morningstar Small-Cap Growth ETFVBKVanguard Extended Market ETFVXFiShares S&P Small-Cap 600 Growth ETFIJTAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
